AtriCure Medical (ATRC): רווח למניה בשנים עשר החודשים האחרונים
Net income per share over the last 12 months allows for an assessment of AtriCure, Inc. (ATRC) success, leveraging the brand's authority in arrhythmia treatment. However, logistics disruptions and sanctions create supply chain risks. High barriers to entry and FDA patents protect the company from competitors. Currently, this metric stands at 0.30, which helps in the timely detection of margin compression and capital risks.
פילוחים אנליטיים של חברת AtriCure Inc (ATRC)
Net income per share over 12 months measures the actual efficiency of capital generation, adjusted for shareholder dilution and benchmarked against book value. The trend of the rolling 12-month earnings per share reflects the valuation's sensitivity to operational successes, where the stability of this metric for AtriCure, Inc. (ATRC) confirms the reliability of cardiac surgery equipment supply chains and the efficiency of safety stock management for components.
